AU2004232835B2 - Screen for pre-eclampsia - Google Patents
Screen for pre-eclampsia Download PDFInfo
- Publication number
- AU2004232835B2 AU2004232835B2 AU2004232835A AU2004232835A AU2004232835B2 AU 2004232835 B2 AU2004232835 B2 AU 2004232835B2 AU 2004232835 A AU2004232835 A AU 2004232835A AU 2004232835 A AU2004232835 A AU 2004232835A AU 2004232835 B2 AU2004232835 B2 AU 2004232835B2
- Authority
- AU
- Australia
- Prior art keywords
- adma
- woman
- eclampsia
- risk
- developing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 49
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims abstract description 71
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims abstract description 68
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims abstract description 43
- 208000030941 fetal growth restriction Diseases 0.000 claims abstract description 43
- 210000003754 fetus Anatomy 0.000 claims abstract description 27
- 230000035935 pregnancy Effects 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 32
- HVPFXCBJHIIJGS-LURJTMIESA-N N(omega),N'(omega)-dimethyl-L-arginine Chemical compound CN\C(=N/C)NCCC[C@H](N)C(O)=O HVPFXCBJHIIJGS-LURJTMIESA-N 0.000 claims description 23
- 210000000685 uterine artery Anatomy 0.000 claims description 16
- 210000002302 brachial artery Anatomy 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000010339 dilation Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 10
- 230000008774 maternal effect Effects 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002146 bilateral effect Effects 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 12
- 229930064664 L-arginine Natural products 0.000 description 10
- 235000014852 L-arginine Nutrition 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 108010048054 dimethylargininase Proteins 0.000 description 6
- 229960003711 glyceryl trinitrate Drugs 0.000 description 6
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000016503 Dimethylarginine dimethylaminohydrolases Human genes 0.000 description 5
- 206010020565 Hyperaemia Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000003205 diastolic effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 208000002296 eclampsia Diseases 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 230000036266 weeks of gestation Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 3
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 229940054441 o-phthalaldehyde Drugs 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 208000022064 reactive hyperemia Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 description 2
- GEICAQNIOJFRQN-UHFFFAOYSA-N 9-aminomethyl-9,10-dihydroanthracene Chemical compound C1=CC=C2C(CN)C3=CC=CC=C3CC2=C1 GEICAQNIOJFRQN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000003708 edge detection Methods 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N 2-azaniumyl-5-[(n'-methylcarbamimidoyl)amino]pentanoate Chemical compound CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308967.9A GB0308967D0 (en) | 2003-04-17 | 2003-04-17 | Screen for pre-eclampsia |
| GB0308967.9 | 2003-04-17 | ||
| PCT/GB2004/001701 WO2004095032A1 (en) | 2003-04-17 | 2004-04-19 | Screen for pre-eclampsia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004232835A1 AU2004232835A1 (en) | 2004-11-04 |
| AU2004232835B2 true AU2004232835B2 (en) | 2009-10-22 |
Family
ID=9956995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004232835A Ceased AU2004232835B2 (en) | 2003-04-17 | 2004-04-19 | Screen for pre-eclampsia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070185200A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1616195B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4489070B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1802566A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE377757T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004232835B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2522285C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004009909T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1616195T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2295857T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0308967D0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ543067A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1616195T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004095032A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053741A1 (en) * | 2005-03-30 | 2009-02-26 | Patrick John Thompson Vallance | Assay for measuring asymmetric methylarginine in a biological sample |
| GB0600916D0 (en) * | 2006-01-17 | 2006-02-22 | Perkinelmer Instr Las Inc | detecting and predicting pre-eclampsia |
| CA2644499A1 (en) * | 2006-03-02 | 2007-09-13 | Perkinelmer Las, Inc. | Methods for distinguishing isomers using mass spectrometry |
| WO2010091253A1 (en) | 2009-02-06 | 2010-08-12 | Women & Infants' Hospital Of Rhode Island | Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy |
| CA2759534C (en) * | 2009-04-23 | 2018-03-27 | Wallac Oy | Method for determining maternal health risks |
| HRP20150802T1 (xx) * | 2010-03-24 | 2015-11-06 | Preelumina Diagnostics Ab | Hbf i a1m kao markeri za rano otkrivanje preeklampsije |
| US20130130278A1 (en) * | 2011-11-22 | 2013-05-23 | Ottawa Hospital Research Institute | Detection of risk for pregnancy-related medical conditions |
| IN2014CN03826A (cg-RX-API-DMAC7.html) * | 2011-11-30 | 2015-10-16 | Koninkl Philips Nv | |
| CN102628868B (zh) * | 2011-12-30 | 2014-09-17 | 北京九强生物技术股份有限公司 | 检测非对称二甲基精氨酸含量的胶乳增强免疫比浊法试剂盒 |
| RU2754956C1 (ru) * | 2021-04-06 | 2021-09-08 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ прогнозирования риска развития преэклампсии у беременных с синдромом задержки роста плода |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811416A (en) * | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| DE10040904A1 (de) * | 2000-08-18 | 2002-02-28 | Boeger Rainer H | Verfahren und Mittel zum Nachweis einer Wahrscheinlichkeit zukünftigen Fortschreitens von Gefässerkrankungen |
| AU2003290784A1 (en) * | 2002-11-15 | 2004-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for detecting asymmetric dimethylarginine in a biological sample |
-
2003
- 2003-04-17 GB GBGB0308967.9A patent/GB0308967D0/en not_active Ceased
-
2004
- 2004-04-19 ES ES04728206T patent/ES2295857T3/es not_active Expired - Lifetime
- 2004-04-19 DK DK04728206T patent/DK1616195T3/da active
- 2004-04-19 EP EP04728206A patent/EP1616195B1/en not_active Expired - Lifetime
- 2004-04-19 DE DE602004009909T patent/DE602004009909T2/de not_active Expired - Lifetime
- 2004-04-19 WO PCT/GB2004/001701 patent/WO2004095032A1/en not_active Ceased
- 2004-04-19 JP JP2006506152A patent/JP4489070B2/ja not_active Expired - Fee Related
- 2004-04-19 AT AT04728206T patent/ATE377757T1/de active
- 2004-04-19 US US10/553,462 patent/US20070185200A1/en not_active Abandoned
- 2004-04-19 NZ NZ543067A patent/NZ543067A/en not_active IP Right Cessation
- 2004-04-19 PL PL04728206T patent/PL1616195T3/pl unknown
- 2004-04-19 AU AU2004232835A patent/AU2004232835B2/en not_active Ceased
- 2004-04-19 CN CNA2004800160908A patent/CN1802566A/zh active Pending
- 2004-04-19 CA CA2522285A patent/CA2522285C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2522285C (en) | 2013-01-22 |
| PL1616195T3 (pl) | 2008-03-31 |
| EP1616195B1 (en) | 2007-11-07 |
| DK1616195T3 (da) | 2008-03-10 |
| US20070185200A1 (en) | 2007-08-09 |
| CA2522285A1 (en) | 2004-11-04 |
| GB0308967D0 (en) | 2003-05-28 |
| NZ543067A (en) | 2008-04-30 |
| AU2004232835A1 (en) | 2004-11-04 |
| CN1802566A (zh) | 2006-07-12 |
| JP2006524325A (ja) | 2006-10-26 |
| DE602004009909D1 (de) | 2007-12-20 |
| DE602004009909T2 (de) | 2008-08-28 |
| JP4489070B2 (ja) | 2010-06-23 |
| HK1081269A1 (en) | 2006-05-12 |
| EP1616195A1 (en) | 2006-01-18 |
| WO2004095032A1 (en) | 2004-11-04 |
| ATE377757T1 (de) | 2007-11-15 |
| ES2295857T3 (es) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5903270B2 (ja) | ガレクチン−３の免疫アッセイ | |
| Salako et al. | Serum albumin, creatinine, uric acid and hypertensive disorders of pregnancy | |
| CN105934671B (zh) | 用于评估妊娠糖尿病的方法和试剂 | |
| AU2013303302B2 (en) | Nt-proCNP as a biomarker of vascular disorders and pregnancy complication | |
| Hendrix et al. | Maternal vascular malformation in the placenta is an indicator for fetal growth restriction irrespective of neonatal birthweight | |
| CN104749384A (zh) | 确定母体健康风险的方法 | |
| CN102224422A (zh) | 使用pigf-2和pigf-3标志物确定先兆子痫风险的方法 | |
| AU2004232835B2 (en) | Screen for pre-eclampsia | |
| CA3027343C (en) | Markers and their ratio to determine the risk for early-onset preeclampsia | |
| EA024188B1 (ru) | МАРКЕРЫ HbF И A1M В КАЧЕСТВЕ МАРКЕРОВ РАННЕЙ СТАДИИ ПРЕЭКЛАМПСИИ | |
| US20130210040A1 (en) | Diagnostic method | |
| JP2017516119A (ja) | 初期胎盤インスリン様ペプチド（プロ（ｐｒｏ）−ＥＰＩＬ） | |
| WO2025111763A1 (zh) | 一种子痫前期风险评估预测模型的构建方法及其应用 | |
| HK1081269B (en) | Screen for pre-eclampsia | |
| Singh et al. | Correlation of Mid-Trimester spot urinary albumin: creatinine ratio with the adverse pregnancy outcome | |
| Mokhtar et al. | Maternal serum perlecan and ischemia modified albumin levels as biomarkers of preeclampsia severity | |
| Zuhal et al. | Comparison of serum ischemia modified albumin levels between preeclamptic and healthy pregnant women | |
| Wu et al. | Reference intervals of renal function set established for healthy pregnant women | |
| Barati et al. | Association of preeclampsia, placental pathology, and maternal-fetal features with gestational hypertension before and after 34 weeks of pregnancy: Preeclampsia and Placental pathology | |
| MS | EARLY DETECTION OF HELLP SYNDROME USING BIOLOGICAL MARKERS AND DOPPLER ULTRASONOGRAPHY | |
| Bersinger et al. | Serum markers for pre-eclampsia: An update on the analytes to be determined in the first, second, and third trimester | |
| Sebire et al. | Placental Fetal Growth Histopathology Restriction Findings in | |
| Lumbiganon et al. | Monitoring in Pre‐Eclampsia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |